Budigalimab  (Synonyms: ABBV 181; PR 1648817)

Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

PDCD1/PD-1/CD279

Budigalimab releases T cell checkpoint inhibition and enhances T cell activity. Budigalimab induces the expression of multiple cytokines and chemokines, including IFN-γ, IL-6, CXCL9/CXCL10, which are involved in the activation and recruitment of T cells, promoting antitumor immune response^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

5133  [NCBI]

Q15116

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.76 kDa

2098225-93-3

Liquid

Colorless to light yellow

[Budigalimab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Human PD-1 Protein (ECD, His Tag) can bind Budigalimab. The EC₅₀ for this effect is 1.43 ng/mL.
• 
  Flow cytometric analysis of 1X10⁶ 10 ng/mL PMA and 1 μg/mL Ionomycin co-stimulated Jurkat cells(24h) with Budigalimab (HY-P99489, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Powderly J, et al. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181). Clin Transl Sci. 2021 Jan;14(1):277-287.  [Content Brief]

  [2]. Lambert SL, et al., Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab. J Immunother. 2022 Apr 1;45(3):167-179.  [Content Brief]